BioCentury
ARTICLE | Clinical News

Ibudilast: Additional Phase II data

April 7, 2008 7:00 AM UTC

Additional data from the first year of a 2-year Phase II trial showed that oral MN-166 significantly decreased the progression of new inflammatory lesions to persistent black holes, which MediciNova s...